Literature DB >> 21403400

The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice.

Yanan Yang1, Young-Ho Ahn, Don L Gibbons, Yi Zang, Wei Lin, Nishan Thilaganathan, Cristina A Alvarez, Daniel C Moreira, Chad J Creighton, Philip A Gregory, Gregory J Goodall, Jonathan M Kurie.   

Abstract

Epithelial tumor cells transit to a mesenchymal state in response to extracellular cues, in a process known as epithelial-to-mesenchymal transition (EMT). The precise nature of these cues has not been fully defined, an important issue given that EMT is an early event in tumor metastasis. Here, we have found that a population of metastasis-prone mouse lung adenocarcinoma cells expresses Notch and Notch ligands and that the Notch ligand Jagged2 promotes metastasis. Mechanistically, Jagged2 was found to promote metastasis by increasing the expression of GATA-binding (Gata) factors, which suppressed expression of the microRNA-200 (miR-200) family of microRNAs that target the transcriptional repressors that drive EMT and thereby induced EMT. Reciprocally, miR-200 inhibited expression of Gata3, which reversed EMT and abrogated metastasis, suggesting that Gata3 and miR-200 are mutually inhibitory and have opposing effects on EMT and metastasis. Consistent with this, high levels of Gata3 expression correlated with EMT in primary tumors from 2 cohorts of lung adenocarcinoma patients. These findings reveal what we believe to be a novel Jagged2/miR-200-dependent pathway that mediates lung adenocarcinoma EMT and metastasis in mice and may have implications for the treatment of human epithelial tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403400      PMCID: PMC3069760          DOI: 10.1172/JCI42579

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

Review 1.  The many facets of Notch ligands.

Authors:  B D'Souza; A Miyamoto; G Weinmaster
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

2.  DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

Authors:  Timothy Hoey; Wan-Ching Yen; Fumiko Axelrod; Jesspreet Basi; Lucas Donigian; Scott Dylla; Maureen Fitch-Bruhns; Sasha Lazetic; In-Kyung Park; Aaron Sato; Sanjeev Satyal; Xinhao Wang; Michael F Clarke; John Lewicki; Austin Gurney
Journal:  Cell Stem Cell       Date:  2009-08-07       Impact factor: 24.633

3.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition.

Authors:  Cameron P Bracken; Philip A Gregory; Natasha Kolesnikoff; Andrew G Bert; Jun Wang; M Frances Shannon; Gregory J Goodall
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

4.  Distinct biological roles for the notch ligands Jagged-1 and Jagged-2.

Authors:  Kuicheon Choi; Young-Ho Ahn; Don L Gibbons; Hai T Tran; Chad J Creighton; Luc Girard; John D Minna; F Xiao-Feng Qin; Jonathan M Kurie
Journal:  J Biol Chem       Date:  2009-04-27       Impact factor: 5.157

Review 5.  Molecular basis of metastasis.

Authors:  Anne C Chiang; Joan Massagué
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

6.  GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors.

Authors:  Antti Kyrönlahti; Maarit Rämö; Maija Tamminen; Leila Unkila-Kallio; Ralf Butzow; Arto Leminen; Mona Nemer; Nafis Rahman; Ilpo Huhtaniemi; Markku Heikinheimo; Mikko Anttonen
Journal:  Endocrinology       Date:  2008-07-24       Impact factor: 4.736

7.  Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis.

Authors:  Shuta Tomida; Toshiyuki Takeuchi; Yukako Shimada; Chinatsu Arima; Keitaro Matsuo; Tetsuya Mitsudomi; Yasushi Yatabe; Takashi Takahashi
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

8.  CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis.

Authors:  Xin-Hai Pei; Feng Bai; Matthew D Smith; Jerry Usary; Cheng Fan; Sung-Yun Pai; I-Cheng Ho; Charles M Perou; Yue Xiong
Journal:  Cancer Cell       Date:  2009-05-05       Impact factor: 31.743

9.  An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.

Authors:  D Chitale; Y Gong; B S Taylor; S Broderick; C Brennan; R Somwar; B Golas; L Wang; N Motoi; J Szoke; J M Reinersman; J Major; C Sander; V E Seshan; M F Zakowski; V Rusch; W Pao; W Gerald; M Ladanyi
Journal:  Oncogene       Date:  2009-06-15       Impact factor: 9.867

10.  Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.

Authors:  Don L Gibbons; Wei Lin; Chad J Creighton; Shuling Zheng; Dror Berel; Yanan Yang; Maria Gabriela Raso; Diane D Liu; Ignacio I Wistuba; Guillermina Lozano; Jonathan M Kurie
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more
  93 in total

1.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

2.  Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis.

Authors:  William K C Cheung; Minghui Zhao; Zongzhi Liu; Laura E Stevens; Paul D Cao; Justin E Fang; Thomas F Westbrook; Don X Nguyen
Journal:  Cancer Cell       Date:  2013-05-23       Impact factor: 31.743

3.  Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling.

Authors:  Alessandro Cama; Fabio Verginelli; Lavinia Vittoria Lotti; Francesco Napolitano; Annalisa Morgano; Andria D'Orazio; Michele Vacca; Silvia Perconti; Felice Pepe; Federico Romani; Francesca Vitullo; Filippo di Lella; Rosa Visone; Massimo Mannelli; Hartmut P H Neumann; Giancarlo Raiconi; Carlo Paties; Antonio Moschetta; Roberto Tagliaferri; Angelo Veronese; Mario Sanna; Renato Mariani-Costantini
Journal:  Acta Neuropathol       Date:  2013-08-18       Impact factor: 17.088

4.  RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.

Authors:  May Chammaa; Agnes Malysa; Carlos Redondo; Hyejeong Jang; Wei Chen; Gerold Bepler; Rodrigo Fernandez-Valdivia
Journal:  J Cell Physiol       Date:  2018-06-28       Impact factor: 6.384

5.  KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells.

Authors:  Baotong Zhang; Zhiqian Zhang; Siyuan Xia; Changsheng Xing; Xinpei Ci; Xin Li; Ranran Zhao; Sha Tian; Gui Ma; Zhengmao Zhu; Liya Fu; Jin-Tang Dong
Journal:  Mol Cell Biol       Date:  2013-10-14       Impact factor: 4.272

6.  ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.

Authors:  Yanan Yang; Young-Ho Ahn; Yulong Chen; Xiaochao Tan; Lixia Guo; Don L Gibbons; Christin Ungewiss; David H Peng; Xin Liu; Steven H Lin; Nishan Thilaganathan; Ignacio I Wistuba; Jaime Rodriguez-Canales; Georgia McLendon; Chad J Creighton; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

7.  Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas.

Authors:  Don L Gibbons; Chad J Creighton
Journal:  Dev Dyn       Date:  2017-05-04       Impact factor: 3.780

8.  Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer.

Authors:  Mark J Schliekelman; Don L Gibbons; Vitor M Faca; Chad J Creighton; Zain H Rizvi; Qing Zhang; Chee-Hong Wong; Hong Wang; Christin Ungewiss; Young-Ho Ahn; Dong-Hoon Shin; Jonathan M Kurie; Samir M Hanash
Journal:  Cancer Res       Date:  2011-10-10       Impact factor: 12.701

Review 9.  microRNA-200b as a Switch for Inducible Adult Angiogenesis.

Authors:  Mithun Sinha; Subhadip Ghatak; Sashwati Roy; Chandan K Sen
Journal:  Antioxid Redox Signal       Date:  2015-05-10       Impact factor: 8.401

Review 10.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.